bioRxiv Science⌕ Search

Biology subjects

Jennings, M. J.

Publications and source records attributed to Jennings, M. J..

2 recordsLinked to original sources

Integrated Gait and Pose Analysis Utilizing Computer Vision for Parkinsonian Behavioral Phenotyping in Mice

Synucleinopathies can be biologically advanced before overt parkinsonism is clinically apparent, highlighting the need for objective, sensitive motor endpoints. We examined the mThy1--synuclein line 61 (L61-Tg) mouse, which shows progressive synucleinopathy with early circuit dysfunction, using an integrated pipeline combining CatWalk XT gait analysis and markerless pose estimation from the same CatWalk videos. Two cohorts of male L61-Tg and nontransgenic littermates were assessed at 12 and 18 months. DeepLabCut tracking of four landmarks showed highest accuracy at the tail base. We thus quantified mediolateral instability as within-run variance of tail-base lateral position. L61-Tg mice exhibited increased tail-base lateral variance at both ages. CatWalk mixed-effects modeling identified six genotype-dependent parameters at 12 months, and a progressive increase in hind base of support at 18 months. Comparison across measures showed that discrimination between L61-Tg and non-transgenic was similarly high for hind base of support and tail-base lateral instability the two were nonetheless synergistic, and the approaches are therefore complementary to one-another in the determination of synucleinopathy motor phenotypes. This combined gait-pose strategy provides scalable, interpretable endpoints for preclinical Parkinson-like phenotyping and therapeutic testing.

neuroscience↗

A genetically encoded fluorescent sensor enables sensitive and specific detection of IDH mutant associated oncometabolite D-2-hydroxyglutarate

D-2-hydroxyglutarate (D-2-HG) is an oncometabolite that accumulates due to mutations in isocitrate dehydrogenase 1 and 2 (IDH1/2). D-2-HG may be used as a surrogate marker for IDH1/2 mutant cancers, yet simple and specific methods for D-2-HG detection are limited. Here, we present the development and characterization of a genetically encoded fluorescent sensor of D-2-HG (D2HGlo). D2HGlo responds to clinically relevant concentrations of D-2-HG, demonstrates exceptional selectivity and can quantify D-2-HG in various body fluids and glioma tumor supernatants. Additionally, analysis of tumor lysates using D2HGlo accurately predicted the IDH mutational status of gliomas. Collectively, these results suggest that D2HGlo may be an in vitro diagnostic device for the detection and monitoring of IDH mutant cancers through liquid biopsies. In addition to D2HGlos clinical utility, we also present preliminary findings for its adaptation to the cellular environment. To assess D-2-HG production in living immortalized glioma cells, we engineered D2HGlo sensors that localize to subcellular compartments, which yielded findings of elevated D-2-HG in the cytosol, mitochondria, and nucleus of IDH1 mutant cells.

cancer biology↗